↳ Research overview
What Is DSIP?
DSIP, Delta Sleep-Inducing Peptide, is a nine-amino-acid neuropeptide originally characterised in mid-twentieth-century sleep-neuroscience research. It has been investigated experimentally across sleep-electrophysiology, neuroendocrine-signalling and neurotransmitter-related research contexts.
This guide covers DSIP's identity, its historical research context and the current shape of the published evidence.
For laboratory research context only. PepDirect supplies DSIP as a research material, not for human or veterinary use.
§ Identity
What is DSIP?
DSIP is a nine-amino-acid neuropeptide first isolated from cerebral blood dialysates in experimental sleep research (Monnier & Schoenenberger, 1970s). It has since been investigated in a range of experimental sleep, neuroendocrine and cellular-signalling research settings.
- Compound: Delta Sleep-Inducing Peptide (DSIP)
- Length: 9 amino acids (nonapeptide)
- Sequence: WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
- CAS number: 62568-57-4
- Molecular formula: C35H48N10O15
- Molecular weight: ~848.81 g/mol
- PubChem CID: 68816
Lot-specific identity and purity should be verified against the printed lot number and its corresponding Certificate of Analysis.
§ Name
What does DSIP stand for?
'DSIP' stands for Delta Sleep-Inducing Peptide. The name reflects the historical experimental context in which the peptide was first characterised: delta-wave electrical activity in the rabbit brain during induced sleep states.
The historical name is descriptive of the research setting in which DSIP was originally studied. It does not, by itself, establish that DSIP produces clinically meaningful sleep effects in humans.
§ Sequence
How many amino acids are in DSIP?
Nine. The DSIP sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, which is written in one-letter code as WAGGDASGE.
§ Research context
What has DSIP been studied for?
- Sleep-state research, historical EEG / electrophysiological experiments in animal models.
- Circadian research, experimental studies involving day-night patterns and biological rhythms in laboratory settings.
- Neuroendocrine signalling, reported interactions with growth-hormone, ACTH and other neuroendocrine axes in preclinical models.
- Neurotransmitter-related experimental research, receptor and signalling studies in cellular and animal systems.
- Stress-response animal models, behavioural and neurophysiological endpoints in rodent research.
The research contexts above describe published areas of experimental investigation. PepDirect does not describe DSIP as a treatment for insomnia, as a sleep medication, as a stress-reducing product or as a clinical intervention of any kind.
§ Evidence
How strong is the DSIP evidence?
The DSIP evidence base has notable limitations. Much of the published literature is older, uses heterogeneous methods and originates from a comparatively small research community. Independent replication has been limited, and modern peer-reviewed evidence for consistent clinical outcomes in humans is sparse.
- Older / historical literature, the majority of the DSIP research corpus.
- Heterogeneous methods, sleep endpoints, neuroendocrine endpoints and behavioural endpoints across different models are not directly comparable.
- Animal and laboratory evidence, dominates the mechanistic literature.
- Human clinical evidence, limited in scale and methodological rigour; not a basis for established therapeutic claims.
§ vs Neuro peptides
DSIP and other neuro research peptides
DSIP, Semax and Selank are all peptides that appear in neurobiological and neuropeptide research, but they are chemically distinct compounds with different sequences, origins and research contexts.
Semax is a synthetic heptapeptide derived from ACTH-fragment research (MEHFPGP). Selank is a synthetic heptapeptide derived from tuftsin-related research (TKPRPGP). DSIP is a distinct nonapeptide (WAGGDASGE) with a separate research history. Findings for one should not be transferred to the others.
§ Research product
View the DSIP research product
DSIP is supplied by PepDirect as a lyophilised research material with lot-specific documentation.
§ References
Selected research references
- DSIP / emideltide · PubChem CID 68816PubChem (NCBI)
- Delta sleep-inducing peptide, chemistry and biology overviewPubMed · Schoenenberger
- DSIP and sleep, historical neuropeptide research reviewPubMed · Graf & Kastin
- Neuropeptides and sleep, experimental research reviewPubMed · Kastin & Fabre
§ FAQ
Frequently asked questions
- What is DSIP?
- DSIP is a nine-amino-acid neuropeptide (Delta Sleep-Inducing Peptide) originally isolated in mid-twentieth-century sleep-neuroscience research and investigated experimentally in sleep, circadian, neuroendocrine and neurotransmitter-related contexts.
- What does DSIP stand for?
- Delta Sleep-Inducing Peptide, a name reflecting its original characterisation in delta-wave EEG sleep experiments.
- What is the DSIP sequence?
- Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), a nine-residue peptide.
- Is DSIP an established treatment for insomnia?
- No. Published human research on DSIP is limited in scale and methodological rigour and does not establish DSIP as a clinical treatment for insomnia or any other condition.
- What types of research involve DSIP?
- Experimental sleep, circadian, neuroendocrine-signalling, neurotransmitter-related and stress-response research, largely in animal and laboratory models.
- Is DSIP the same as Semax or Selank?
- No. DSIP, Semax and Selank are chemically distinct peptides with different sequences, different origins and separate research literatures.
- Is PepDirect DSIP intended for human use?
- No. DSIP is supplied strictly as a laboratory research material. It is not marketed as a medicine, food supplement or product for human or veterinary use.
§ Related